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Introduction {#sec1}
============

Foxp3 is the master transcription factor (TF) for regulatory T (T~reg~) cells, and its absence leads to catastrophic autoimmune events in mice (Scurfy phenotype; [@bib6], [@bib15], [@bib49]) and humans (IPEX or immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome; [@bib5]). Foxp3 expression in concert with a specific epigenetic landscape induced in the thymus defines T~reg~ cells ([@bib30]). A subset of T~reg~ cells can acquire epigenetic and transcriptional profiles defining their tissue adaptation ([@bib11], [@bib12], [@bib10], [@bib37]).

The *Foxp3* gene is located on the X chromosome. It contains 14 exons, three of which are not translated (-2a, -2b, and −1). The promoter with TATA box, GC box, and CAAT box is located just upstream of the transcription start site (TSS). When comparing the sequence homology between mouse and human *Foxp3* genetic code, a high degree of conservation can be appreciated for the coding exons, three regions in non-coding introns, and the promoter itself ([@bib2], [@bib19], [@bib35], [@bib51]). The three distinct conserved regions within the intronic sequences of the *Foxp3* gene were determined as conserved non-coding sequences 1, 2, and 3 (CNS1-3). Each CNS region has a distinct function in the initiation or stabilization of *Foxp3* gene expression, just like the core *Foxp3* promoter ([@bib13], [@bib33]). A fourth conserved region outside the Foxp3 gene, named CNS0, has recently been described ([@bib22]).

CNS0 contains T~reg~-specific super-enhancers crucial for T~reg~ cell lineage specification in the thymus ([@bib22]). CNS1 is an important transforming growth factor (TGF)-β-sensitive enhancer region for the induction of peripherally induced T~reg~ (pT~reg~) from Foxp3^-^ conventional CD4 T (T~conv~) cells *in vivo* and for the *in vitro* conversion of T~reg~ cells from T~conv~. CNS1 is not relevant for thymic T~reg~ cell generation ([@bib20], [@bib36], [@bib41]). The CNS2 region contains a high number of CpG sites, becomes demethylated in the thymus, and has an important role to stabilize Foxp3 expression ([@bib11], [@bib14], [@bib57]). In addition, some factors bind this region to stabilize the demethylated phenotype ([@bib21], [@bib27]). The CNS3 is a pioneer element required for efficient induction of *Foxp3* transcription ([@bib38], [@bib57]).

The precise location of the *Foxp3* promoter and the true TSS were identified in a study utilizing rapid amplification of 5′ ends, proving that the core promoter is indeed the area where DNA-dependent RNA transcription of *Foxp3* pre-mRNA begins ([@bib41]).

Several studies identified Nfat (nuclear factor of activated T cells) binding to the *Foxp3* promoter, and mutations in the *Nfat*-binding sites or deficiency in calcium sensing disrupted its activity ([@bib24], [@bib29], [@bib41]). In addition, a set of Forkhead Box proteins (Foxo1 and Foxo3a) bind the *Foxp3* promoter as part of the PI3K-Akt-mTOR pathway, and their specific deletion caused multifocal inflammatory disorder ([@bib17], [@bib31]). Stat5 (signal transducer of activated T cells 5) has also been detected at the *Foxp3* gene promoter, and its selective deletion prevents T~reg~ cell development ([@bib8], [@bib55]). Another example of direct *Foxp3* promoter regulation is the study of nuclear receptor subfamily members: mice devoid of all three subfamily members (Nr4a1, Nr4a2, Nr4a3) cannot produce T~reg~ cells and die of systemic autoimmunity ([@bib39], [@bib40]). Several studies identified the c-Rel enhanceosome complex ([@bib32]) as well as Runx proteins ([@bib7], [@bib23]) at the *Foxp3* promoter. Finally, *Foxp3*-promoter-binding partners have been identified in the E2A-Id3 signaling axis and have been shown to influence Foxp3 expression ([@bib47], [@bib50]).

These studies have identified an impressive set of Foxp3-inducing factors. However, much less is known about Foxp3-repressive factors required to protect Foxp3-negative T~conv~ cells from unwanted Foxp3 expression, e.g., as a by-product of T cell activation.

We wanted to identify *Foxp3*-promoter-binding proteins in an unbiased way using quantitative mass spectrometry ([@bib26]). With this approach, we identified several binding partners to the *Foxp3* promoter region with repressive effect on the *Foxp3* promoter. One of those Foxp3-promoter-suppressive factors was T cell factor 1 (TCF1), which we followed up by Luciferase-based-binding studies, by overexpression and deletion studies in primary T cells, and by the analysis of a TCF1-deficient mouse strain. Our data point toward a specific role of TCF1 to suppress Foxp3 expression in activated non-T~reg~ cells.

Results {#sec2}
=======

Quantitative Proteomics Identifies *Foxp3*-Promoter-Binding Factors {#sec2.1}
-------------------------------------------------------------------

We visualized the conservation of *Foxp3* genetic code between mouse and human and superimposed the *Foxp3* gene structure to identify target regions for protein binding identification ([Figure 1](#fig1){ref-type="fig"}A). We could observe that the *Foxp3* gene promoter, at least in its very proximal 500 bp, was highly conserved between mouse and human. In addition, the proximal promoter was demethylated in both T~reg~ and T~conv~ cells, whereas intron-1 was specifically demethylated only in T~reg~ cells. We generated three 500-bp DNA probes complementary to the *Foxp3* promoter region: *Foxp3*-Fra1, starting from the *Foxp3* TSS and extending 500 bp upstream into the promoter region (−500); *Foxp3*-Fra2, extending −500 bp to −1000 bp into the *Foxp3* promoter; and *Foxp3*-Fra3, extending from −1000 bp to −1500 bp into the distal *Foxp3* promoter region ([Figure 1](#fig1){ref-type="fig"}A). All three fragments were generated with biotin-labeled primers to use them as probes for an *in vitro* pull-down followed by mass spectrometry ([@bib26]) ([Figure 1](#fig1){ref-type="fig"}B). First, streptavidin beads were linked to biotinylated *Foxp3* promoter Fra1, Fra2, or Fra3 probes, followed by incubation with nuclear proteins isolated from EL4 T cells. We used EL4 T cells as a Foxp3-negative cell line to study potential repressive elements binding to the Foxp3 promoter. Unbound protein was washed off, and beads including attached proteins were isolated in a magnetic field. Protein was eluted from the beads and purified, digested, labeled with stable isotopes, fractionated, and finally subjected to nano-liquid chromatography-mass spectrometry analysis allowing the quantitative detection of peptides bound to each DNA probe.Figure 1Quantitative Proteomics of the *Foxp3* Promoter(A) Conservation between mouse (CCDS29965) and human (CCDS14323) *Foxp3* genetic code. The y axis indicates conservation between genetic code in %, and the x axis indicates genomic location. Histogram generated with Vista ([@bib25]). Labels PRO (promoter) and CNS (conserved non-coding sequence) on top. Below, CG methylation of the *Foxp3* gene (X:7,579,676-7,595,243) with three replicate T~reg~ and T~conv~ cells, data published previously ([@bib11]). Beneath histograms, magnification of the *Foxp3* promoter region from −1600 bp to +300 bp relative to the Foxp3 TSS with methylation levels of individual CGs. Probes for proteomics are labeled in orange.(B) Overview of the quantitative proteomics procedure. First, beads are loaded with biotinylated *Foxp3*-Fra1, *Foxp3*-Fra2, or *Foxp3*-Fra3 probes (Loading \[1\]). Then, loaded beads are incubated with nuclear proteins and purified in magnetic field (Affinity pull-down \[2\]). Proteins are denatured (Denaturation \[3\]) and purified (Purification \[4\]), followed by Fractionation (5) and Detection (6) via nano-liquid chromatography-tandem mass spectrometry (LC-MS/MS).

The experiment was done in two replicates, yielding more than 2,500 proteins bound to each DNA probe ([Figure 2](#fig2){ref-type="fig"}A). Of the around 2,400 proteins that could be quantified with each probe, 43, 23, and 23 were differentially bound to Fra1, Fra2, and Fra3, respectively (fold-change log~2~\>3 compared with the other two probes, false discovery rate \[FDR\] \<1%). All binding partners to Fra1 are displayed in a dot plot for relative binding as well as a volcano plot to visualize selection based on statistics (p \< 0.01) and fold-change (log~2~\>3, [Figure 2](#fig2){ref-type="fig"}B). Proteins with positive binding values (in the comparison Fra1 versus Fra2 and Fra1 versus Fra3) were identified and labeled in red, whereas proteins with negative binding values (e.g., not binding to Fra1, but to Fra2 or Fra3) were labeled in blue. Proteins that bound equally to both fragments were labeled in gray. A heatmap with differential binding values for all selected proteins for Fra1 clarifies selective binding patterns of all candidate factors: out of the 43 proteins that bound differentially to Fra1 versus Fra2 and Fra 1 versus Fra3, 41 were enriched on Fra1, being potential candidates for downstream testing. Two proteins bound strongly to Fra2 or Fra3, but not Fra1, and were excluded.Figure 2Proteins Identified at the *Foxp3* Promoter(A) Results of quantitative proteomics of the *Foxp3* promoter with two replicates; FDR, false discovery rate. Bold numbers indicate differential binding partners to the respective fragment (FDR 1%, fold-change log2\>3). Red numbers indicate positive binding partners, blue numbers negative binding partners to the respective fragment.(B) Results for *Foxp3*-Fra1. Left dot plots illustrate all detected proteins with relative binding values to Fra1 versus Fra3 (y axis) and Fra1 versus Fra2 (x axis). Right graph, volcano plot with Fra1 versus Fra2 relative binding (x axis) versus adjusted p value (y axis). Key genes are highlighted. Positive and negative binding partners (FDR 1%, fold-change log2\>3) are highlighted.(C) Heatmap illustrating relative binding of Fra1 candidates to Fra1, Fra2, and Fra3 (FDR 1%, fold-change log2\>3).(D) Results for *Foxp3*-Fra2. Left dot plots illustrate all detected proteins with relative binding values to Fra2 versus Fra3 (y axis) and Fra2 versus Fra1 (x axis). Right graph, volcano plot with Fra2 versus Fra3 relative binding (x axis) versus adjusted p value (y axis). Key genes are highlighted. Positive and negative binding partners (FDR 1%, fold-change log2\>3) are highlighted.(E) Heatmap illustrating relative binding of Fra2 candidates to Fra1, Fra2, and Fra3 (FDR 1%, fold-change log2\>3).(F) Results for *Foxp3*-Fra3. Left dot plots illustrate all detected proteins with relative binding values to Fra3 versus Fra2 (y axis) and Fra3 versus Fra1 (x axis). Right graph, volcano plot with Fra3 versus Fra1 relative binding (x axis) versus adjusted p value (y axis). Key genes are highlighted. Positive and negative binding partners (FDR 1%, fold-change log2\>3) are highlighted.(G) Heatmap illustrating relative binding of Fra3 candidates to Fra1, Fra2, and Fra3 (FDR 1%, fold-change log2\>3). Data are representative of two independent experiments.

To identify candidates\' binding to Fra2, we again display dot plot and heatmap ([Figures 2](#fig2){ref-type="fig"}D and [2](#fig2){ref-type="fig"}E). Of the 23 proteins that bound differentially to Fra2 versus Fra1 and Fra2 versus Fra3, five bound specifically to Fra2. All other candidates bound strongly to Fra1 or Fra3 and were excluded for downstream testing. For Fra3, 5 of 12 proteins were enriched on the Fra3-binding sites and used to select candidate factors ([Figures 2](#fig2){ref-type="fig"}F and [2](#fig2){ref-type="fig"}G). Therefore, in summary, we identified 41 factors bound to Fra1, 5 factors bound to Fra2, and 5 factors bound to Fra3.

*Foxp3*-Promoter-Binding TFs Down-modulate *Foxp3* Promoter Activity *In Vitro* {#sec2.2}
-------------------------------------------------------------------------------

For our proteomics experiments, we used nuclear protein derived from a T cell line. To avoid cell line artifacts, we measured expression levels of some candidate factors in primary murine T~reg~ and T~conv~ cells as well as in EL4 and RMA mouse T cell lines by real-time PCR. Most factors were expressed in primary T~reg~ and T~conv~ cells and cell lines ([Figure S1](#mmc1){ref-type="supplementary-material"}A). In addition, we isolated T~reg~ and T~conv~ cells from human peripheral blood and measured the expression of some candidate factors by real-time PCR and included three T cell lines (Jurkat, CEM, and BE, [Figure S1](#mmc1){ref-type="supplementary-material"}B). As seen for mouse, most factors were also expressed in primary human T cells.

To explore the function of candidate proteins with Luciferase reporter vectors, we cloned nine factors from Fra1, five factors from Fra2, and three factors from Fra3 into eukaryotic production vectors. All vectors were sequenced to confirm plasmid identity and sequence integrity, and we verified plasmid stability by gel electrophoresis ([Figure S1](#mmc1){ref-type="supplementary-material"}C). In addition, we confirmed transgene expression for selected transgenes by western blot ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and confirmed plasmid identity ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Using a eukaryotic vector expression system, we transfected the respective candidate factors, a *Foxp3* promoter vector with *Luciferase* reporter ([@bib39]) and a *beta-galactosidase* transfection and normalization control vector into HEK293 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). After 2 days, we measured Luciferase and β-galactosidase enzymatic activity. To cross-validate our dataset, we used a Luciferase basic vector without promoter, a full *Foxp3* promoter Luciferase vector (containing 3,500 bp of the *Foxp3* promoter, location X:7,576,145- X:7,589,866 \[10190 bp\]), and short 500-bp *Foxp3* promoter Luciferase vectors ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These short fragments were identical to the probes used for quantitative proteomics ([Figure 1](#fig1){ref-type="fig"}A). Using this system, we first measured light induction by GFP (negative control) and Nr4a1 (positive control). As expected, GFP expression did not induce activity together with the basic vector, the full *Foxp3* promoter vector, or a vector containing only *Foxp3* Fra1 ([Figure S3](#mmc1){ref-type="supplementary-material"}C, left). In contrast to this, the Nr4a1 transgene induced significant activity at the full *Foxp3* promoter vector, but not in the Fra1 or the basic vector ([Figure S3](#mmc1){ref-type="supplementary-material"}C, right). Nr4a1 binding to the *Foxp3* gene has already been described in the literature ([@bib39], [@bib40]). Next, we tested the candidates identified with our screening method with this assay. None of the factors induced *Foxp3* promoter Luciferase activity in the short (Fra1, Fra2, Fra3) or the full *Foxp3* promoter vector. In contrast to this, some of the factors such as Sf1 (splicing factor 1), Znf574 (zinc finger protein 574), Rfx1 (regulatory factor X,1), or Naa38 (Nα-acetyltransferase 38, NatC auxiliary subunit) showed a significant down-modulation of Luciferase activity at one of the *Foxp3* promoter vectors ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3F). Taken together, our Luciferase screens demonstrate that some of our candidate factors showed significant repressive activity and down-modulated basic *Foxp3* promoter activity.

Candidate Factors Overrule Activation-Induced *Foxp3* Promoter Activity {#sec2.3}
-----------------------------------------------------------------------

In the previous experiments, we identified *Foxp3*-promoter-binding TFs and observed that they down-modulated basic *Foxp3* promoter activity. *Foxp3* promoter signaling can also be induced by T cell receptor (TCR) stimulation ([@bib24], [@bib29], [@bib41]). Therefore, we established a system where Jurkat T cells were electroporated with a *Foxp3* promoter vector, a eukaryotic production vector carrying the candidate transgene, and a *Renilla* normalization and transfection control vector ([Figure S4](#mmc1){ref-type="supplementary-material"}A). After 24 h, TCR signaling was mimicked by phorbol myristate acetate (PMA)/Ionomycin (PMA/IM) stimulation. After 24 h, Luciferase and Renilla activities were measured by luminescence, as before. When comparing results for the basic vector without any promoter sequence and the *Foxp3* promoter vector, PMA/IM stimulation increased *Foxp3* promoter activity by about 10-fold ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We tested several candidate transgenes with this system. No changes were observed when using the basic Luciferase vector. In contrast to this, PMA/IM stimulation induced activity with the *Foxp3* promoter vector. Interestingly, some of the factors such as Pcbp1, Pcbp2, and Thap11 significantly down-regulated Luciferase activity with the *Foxp3* promoter, but not with the basic vector without a promoter sequence ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E). These data indicate that certain TCR signals induced by treatment of cells with PMA/IM can be suppressed by individual candidate factors, providing additional evidence of their *Foxp3*-suppressive nature.

Candidate TF Expression Levels in Primary T~reg~ and T~conv~ Cells Identifies TCF1 {#sec2.4}
----------------------------------------------------------------------------------

In the previous experiments, we confirmed the *Foxp3*-suppressive nature of multiple TFs with our proteomics approach. Now, to select a candidate TF for further evaluation, we used a funnel approach using published proteome datasets. Ideally, a candidate TF should be up-regulated in Foxp3-negative T~conv~ cells. Two recent studies investigated the differential proteome between murine T~reg~ and T~conv~ cells ([@bib3]) and human T~reg~ and T~conv~ cells ([@bib9]). We extracted both datasets and identified our target *Foxp3*-promoter-binding factors. When comparing the 5,129 proteins identified in bulk murine Foxp3^+^ T~reg~ versus Foxp3^-^ T~conv~, we could map 162 of 209 *Foxp3*-promoter-binding factors (fold-change log2\>2, FDR \< 1%) to this dataset ([Figure 3](#fig3){ref-type="fig"}A). One example for a highly significant T~conv~-over-expressed factor that also binds the *Foxp3* promoter in our study is TCF1. When using the dataset derived from human effector T~conv~ versus effector T~reg~ cells, we could map 138 proteins of 209 *Foxp3*-promoter-binding factors ([Figure 3](#fig3){ref-type="fig"}B). Again, TCF1 was detected as T~conv~-specific over-expressed factor. Therefore, human and mouse T~reg~/T~conv~ proteomic datasets indicate that TCF1, a candidate protein identified with our *Foxp3*-promoter-binding screening ([Figures 2](#fig2){ref-type="fig"}B and 2C), is also a differentially expressed TF in Foxp3-positive versus Foxp3-negative T cells. To further validate this, we stained CD4^+^Foxp3^-^ T~conv~ cells, CD4^+^Foxp3^+^ T~reg~ cells, and CD4^−^CD8^+^ cytotoxic T cells and measured TCF1 expression levels by flow cytometry. As a control, we used *Tcf7*^−/−^ animals (*Tcf7*^*−/−*^ animals lack the TCF1 protein) ([@bib44]). In spleen, T~conv~ and CD8 T cells expressed elevated TCF1 levels, whereas T~reg~ cells had significantly lower expression values ([Figure 3](#fig3){ref-type="fig"}C). To test if TCF1 has a repressive function on the *Foxp3* promoter, we used PMA/IM-stimulated Jurkat cells and electroporated a *Tcf7* eukaryotic production vector ([Figure 3](#fig3){ref-type="fig"}D). Interestingly, the TCF1 overexpression showed significant capacity to down-modulate the activity of the *Foxp3* promoter, but not the basic promoter ([Figure 3](#fig3){ref-type="fig"}E). In summary, we showed that TCF1 is expressed more specifically in Foxp3-negative T~conv~ cells and that the TCF1 protein has the capacity to down-modulate *Foxp3* promoter activity, similar to other proteins identified by quantitative proteomics of the *Foxp3* promoter.Figure 3Funnel Approach Identifies TCF1 as Foxp3-Regulating TF(A) 5,129 proteins comparing bulk murine Foxp3^+^ T~reg~ versus Foxp3^-^ T~conv~ were extracted from [@bib3] and compared with our proteomics dataset. Data are displayed in a volcano plot with adjusted p value (y axis) versus protein expression T~reg~ versus T~conv~ (x axis). 162 out of 209 *Foxp3*-promoter-binding factors (fold-change log2\>2, FDR\<1%) were mapped to this dataset and highlighted in red. Key TF labeled.(B) 4,331 proteins comparing bulk human effector T~reg~ versus T~conv~ were extracted from [@bib9] and compared with our proteomics dataset. Data are displayed in a volcano plot with adjusted p value (y axis) versus protein expression T~reg~ versus T~conv~ (x axis). 138 of 209 *Foxp3*-promoter-binding factors (fold-change log2\>2, FDR\<1%) were mapped to this dataset and highlighted in red. Key TF labeled.(C) Analysis of TCF1 protein expression in *Tcf7*^+/+^ animals (top) and *Tcf7*^−/−^ animals (below). Left, dot plots illustrating TCF1 expression in T~reg~ cells (CD8^−^CD4^+^Foxp3^+^), T~conv~ cells (CD8^−^CD4^+^Foxp3^-^), and CD8 T cells (CD4^−^CD8^+^). Right, statistical analysis across replicates (n = 4, one-way ANOVA, error bars = standard deviation, ∗∗∗p \< 0.001).(D) Experiment overview: 2,000,000 Jurkat cells were electroporated with a Renilla normalization vector, *Foxp3*-Luciferase reporter vector, and a eukaryotic expression vector containing the transgene of interest; 24 h after electroporation, cells were stimulated with PMA/Ionomycin, and 20 h after stimulation, cells were lysed and Renilla as well as Luciferase enzyme activities were measured on a luminometer with automated injection of substrates.(E) Jurkat cells were electroporated with a Renilla normalization vector, *Foxp3*-Luciferase reporter vector, and a *GFP* or *TCF1* eukaryotic expression vector. Statistical testing with unpaired t test (n = 3--16, ∗p \< 0.05). Data are derived from literature or two or more independent experiments.

TCF1 Overexpression Impairs Foxp3 Induction {#sec2.5}
-------------------------------------------

To validate the impact of TCF1 on *Foxp3* gene expression in mature T~reg~ cells, we transduced primary T~reg~ cells with a *Tcf7*-MSCV retrovirus, with CD90.1 as a reporter for viral transduction and transgene expression ([Figure 4](#fig4){ref-type="fig"}A). The percentage of Foxp3 expression remained high in both *Tcf7*- and control-virus-transduced T~reg~ cells and was not affected by TCF1 protein production. In contrast to this, the Foxp3 median fluorescence intensity (MFI) was significantly reduced in TCF1-overexpressing T~reg~ cells, indicating that TCF1 can influence *Foxp3* gene expression in mature T~reg~ cells ([Figure 4](#fig4){ref-type="fig"}B). In line with this finding, we wanted to test the influence of TCF1 on the *de novo* induction of Foxp3 expression. To do so, we over-expressed TCF1 or a control protein in T~conv~ cells under TGF-β differentiation conditions, followed by measurement of intracellular Foxp3 levels ([Figure 4](#fig4){ref-type="fig"}C). Indeed, upon over-expressing TCF1, Foxp3 levels were reduced in percent and MFI, indicating that TCF1 also restrains Foxp3 induction ([Figure 4](#fig4){ref-type="fig"}D). Our data indicate that TCF1 impairs Foxp3 induction and maintenance *in vitro*.Figure 4Effect of TCF1 Overexpression on Thymus-Derived thymic T~reg~ or *In Vitro* Converted iT~reg~ Cells(A) Experiment overview: Primary murine CD4^+^CD25^+^*Foxp3*(GFP)^+^ T~reg~ cells were purified by fluorescence-activated cell sorting (FACS), stimulated with anti-CD3/28 beads plus interleukin-2, and expanded for 48 h at 37°C. Then, virus-containing supernatant derived from PhxEco producer cells was harvested and T cells were virally transduced for 7 h at 37°C. T cells were allowed to recover and express the transgene for 60 h at 37°C, following intracellular flow cytometry to determine Foxp3 protein expression levels.(B) Representative pseudocolor plots for ctrl MSCV virus and *Tcf7*-MSCV virus-treated T~reg~ cells. Virus-transduced cells are CD90.1^+^, whereas non-transduced cells are CD90.1^-^. From CD90.1^+^ gate, Foxp3 expression can be determined. Numbers indicate positive cells in the gate in %. Axis labels indicate fluorescence intensity. MFI based on Foxp3 gate. Statistical quantification to the right (n = 7, unpaired t test, ∗p \< 0.05 and ns p \> 0.05).(C) Experiment overview: Primary sorted *Foxp3*(GFP)-negative T~conv~ cells were FACS purified, stimulated with anti-CD3/28 beads, and differentiated with TGF-β for 48 h at 37°C. Then, virus-containing supernatant derived from PhxEco producer cells was harvested, and T cells were virally transduced for 7 h at 37°C. Afterward, T cells were allowed to recover and express the transgene for 60 h at 37°C, following intracellular flow cytometry to determine Foxp3 protein expression levels.(D) Flow cytometry pseudocolor plots for T~conv~ cells treated with a control-MSCV virus or *Tcf7*-MSCV virus. From CD90.1^+^ gate, Foxp3 expression can be determined. To the right, percentage of Foxp3 expression and Foxp3 MFI are evaluated across experiments (unpaired t test, n = 15, ∗∗∗p \< 0.001). Data are derived from two to three independent experiments with individual mice.

TCF1-Deficient Animals Have More CD25^neg^Foxp3^int^ T cells in the Periphery {#sec2.6}
-----------------------------------------------------------------------------

To validate the relevance of TCF1 *in vivo*, we analyzed *Tcf7*^−/−^ animals ([@bib44]). First, we measured the frequency of CD4^+^CD25^+^Foxp3^+^ T~reg~ cells in lymph node and spleen of *Tcf7*^−/−^, *Tcf7*^+/−^, and *Tcf7*^+/+^ (wild-type) animals and detected no obvious differences ([Figure 5](#fig5){ref-type="fig"}A). In contrast to this, we observed about 5-fold elevated numbers of CD25-negative Foxp3-intermediate (CD4^+^CD25^-^Foxp3^int^) T cells (1.56% in *Tcf7*^+/+^ versus 8.82% in *Tcf7*^−/−^). No dosage effect was observed, because heterozygous deletion of *Tcf7* had no effect. Next, we were interested in whether only CD4^+^ T cells were affected by the deletion of TCF1. To answer this, we measured Foxp3 expression in CD8^+^ T cells and CD19^+^ B cells isolated from secondary lymphoid tissues of *Tcf7*^−/−^, *Tcf7*^+/−^, and *Tcf7*^+/+^ animals ([Figures 5](#fig5){ref-type="fig"}B and 5C). In line with our observations with CD4^+^ T cells, we could detect elevated numbers of Foxp3^+^ cells in the CD8^+^ population, although with a lower magnitude ([Figure 5](#fig5){ref-type="fig"}B). Interestingly, no effect was observed when analyzing Foxp3 expression in CD19^+^ B cells ([Figure 5](#fig5){ref-type="fig"}C).Figure 5CD25-Negative Foxp3-Intermediate T cells in TCF1-Deficient Mice(A) Analysis of spleen and lymph node in *Tcf7*^−/−^, *Tcf7*^−/+^, and *Tcf7*^+/+^ mice. CD4 T cells were identified (CD19^−^CD8^−^CD4^+^), and Foxp3 versus CD25 was plotted. Percentage of CD25^-^Foxp3^+^ and CD25^+^Foxp3^+^ of CD4^+^ T cells was calculated (n = 5, one-way ANOVA with Tukey\'s post-test, ∗∗∗p \< 0.001).(B) Analysis of spleen and lymph node in *Tcf7*^−/−^, *Tcf7*^−/+^, and *Tcf7*^+/+^ mice. CD8 T cells were identified (CD19^−^CD8^+^CD4^-^), and Foxp3 versus SSC-A was plotted. Percentage of Foxp3^+^ of CD8^+^ T cells was calculated (n = 5, one-way ANOVA with Tukey\'s post-test, ∗∗∗p \< 0.001).(C) Analysis of spleen and lymph node in *Tcf7*^−/−^, *Tcf7*^−/+^, and *Tcf7*^+/+^ mice. CD19 B cells were identified (CD19^+^CD8^−^CD4^-^) and Foxp3 versus SSC-A was plotted. Percentage of Foxp3^+^ of CD19^+^ B cells was calculated (n = 5, one-way ANOVA with Tukey\'s post-test, ns p \> 0.05).(D) Expression of Foxp3 in CD25^-^Foxp3^+^ and CD25^+^Foxp3^+^ T cells from spleen and lymph node. Representative histograms to the left, and statistical quantification to the right (n = 5, one-way ANOVA with Sidak\'s post-test, ∗∗∗p \< 0.001).(E) Percentage of CD25^-^Ctla4^+^ and CD25^+^Ctla4^+^ in spleens of *Tcf7*^−/−^, *Tcf7*^−/+^, and *Tcf7*^+/+^ mice. Representative dot plots to the left, and statistical quantification to the right (n = 3, one-way ANOVA with Tukey\'s post-test, ∗∗p \< 0.01 and ns p \> 0.05). Data are derived from two or more independent experiments with individual mice.

Are CD25^-^Foxp3^int^ T cells actually T~conv~ cells that express Foxp3 due to the absence of TCF1, a Foxp3-repressive factor? To investigate this, we first measured Foxp3 protein levels via flow cytometry and detected reduced Foxp3 MFI of CD25^-^Foxp3^int^ T~reg~ cells versus CD25^+^Foxp3^+^ "true" T~reg~ cells ([Figure 5](#fig5){ref-type="fig"}D). Next, we stained CTLA-4, a critical factor for T~reg~ identity and function ([Figure 5](#fig5){ref-type="fig"}E). Indeed, we also identified CTLA-4^-^Foxp3^+^ T cells, which are normally almost absent in wild-type animals (0.5% of CD4^+^), but increased in TCF1-deficient animals to about 4% of CD4^+^ T cells. The occurrence of this specific CD25^−^CTLA4^-^Foxp3^int^ population could be the consequence of a less restricted Foxp3 induction potential in TCF1-deficient T cells.

CRISPR-Cas9-Mediated Deletion of TCF1 Induces Foxp3 in Primary T~conv~ Cells {#sec2.7}
----------------------------------------------------------------------------

In *Tcf7*^−/−^ animals, higher fractions of Foxp3-positive T cells were identified. However, these experiments did not tell us whether this was a consequence of an activation event in T~conv~ cells or a thymus-based selection process. To address the possibility that TCF1 restricts "unwanted" Foxp3 expression in T~conv~ cells, we deleted TCF1 in activated T~conv~ cells with CRISPR-Cas9 technology ([Figure 6](#fig6){ref-type="fig"}A). We calibrated the system by knocking out CD5 with a *Cd5* guide RNA (crRNA) and achieved a loss of CD5 protein expression in about 60% TCR-activated primary CD4^+^ T cells ([Figure 6](#fig6){ref-type="fig"}B). Using *Tcf7* crRNA, we observed TCF1 protein loss in about 50% primary CD4^+^ T cells ([Figure 6](#fig6){ref-type="fig"}B). Thus, individual wells contained equal ratios of TCF1-sufficient and TCF1-deficient CD4^+^ T cells, allowing us to directly compare the effect of TCF1 loss on Foxp3 expression under the same conditions. Using different concentrations of TGF-β to induce Foxp3 expression, we identified significantly increased Foxp3 protein expression in TCF1-deleted T~conv~ cells when compared with TCF1-sufficient T~conv~ cells ([Figure 6](#fig6){ref-type="fig"}C).Figure 6CRISPR-Cas9 Knockout of TCF1 Induces Elevated Foxp3 Levels(A) Experiment overview: Primary murine CD4^+^ T cells are stimulated with anti CD3-CD28 beads for 3 days *in vitro*. Then, cells are electroporated with a Cas9 protein, tracrRNA, and a *Tcf7* guide RNA with the Neon electroporation system. Afterward, cells recovered for 3 days at 37°C. Different concentrations of TGF-β were used during proliferation and recovery phase.(B) CRISPR-Cas9-based deletion of CD5 (left) and TCF1 (right) in CD4+ T cells.(C) Results of CRISPR-Cas9-based deletion of TCF1 in murine CD4^+^ T cells. Pseudocolor dot plots illustrate TCF1-positive and TCF1-negative T cell populations after CRISPR-based TCF1 knockout and recovery for 72 h. Foxp3 expression for TCF1-negative and TCF1-positive populations shown to the right. A statistical verification across replicates is shown below (unpaired t test, n = 8, ∗∗∗p \< 0.001 and ns p \> 0.05).(D) Results of CRISPR-Cas9-based deletion of TCF1 in human CD4^+^ T cells. Left, pseudocolor dot plots illustrating TCF1-positive and TCF1-negative T cell populations after CRISPR-based TCF1 knockout (*TCF7* AA guide RNA). Foxp3 expression for TCF1-negative and TCF1-positive populations is shown. A statistical verification across replicates is shown to the right (unpaired t test, n = 8, ∗∗∗p \< 0.001).(E) Human FOXP3-negative T~conv~ cells were treated with *TCF7* AA guide RNA, followed by stimulation with PMA/Ionomycin and treatment with transport inhibitors. After 4 h, T cells were stained for intracellular expression of interleukin-2. A statistical verification across replicates is shown to the right (unpaired t test, n = 8, ∗∗∗p \> 0.001). Data are derived from two independent experiments with individual samples.

To validate our findings in the human system, we used the CRISPR-Cas9 knockout approach to delete TCF1 in human CD4+ T cells. It has been described that a fraction of human CD4 T~conv~ cells spontaneously induces FOXP3 protein expression after TCR activation ([@bib16], [@bib45]). To test if TCF1 is relevant for this spontaneous FOXP3 expression, we stimulated human T~conv~ cells with anti-CD3 and anti-CD28 and observed the cells following CRISPR-Cas9 knockout of TCF1. Even without the addition of TGF-β, we detected significantly more FOXP3-expressing CD4^+^ T cells in TCF1-deleted when compared with TCF1-sufficient T~conv~ cells ([Figure 6](#fig6){ref-type="fig"}D). The FOXP3-positive fraction increased from about 8% of CD4-sufficient T~conv~ cells to about 16% in TCF1-deleted T~conv~ cells. To investigate the inflammatory phenotype of TCF1-deleted FOXP3-positive T cells, we stimulated CRISPR-Cas9-treated T~conv~ cells with a T cell stimulation cocktail containing PMA/IM and blocked cytokine secretion with a transport inhibitor. Interestingly, TCF1-deleted FOXP3-positive T cells produced more interleukin-2 compared with control cells, indicating that TCF1-deleted FOXP3-positive T cells might indeed produce FOXP3 as a bystander effect of TCR stimulation, but do not exert the regulatory phenotype associated with a classical T~reg~ cell. Therefore, in summary, our data indicate that TCF1 protects T~conv~ cells from activation-induced FOXP3 expression.

Discussion {#sec3}
==========

Several TFs can bind to the *Foxp3* promoter. They modulate the downstream functions by direct binding to the promoter and initiation of transcription, via the recruitment of co-activators, by the selective displacement of repressive TFs, or by epigenetic modulation of the promoter ([@bib13]). It is believed that many factors co-operate in a context-dependent manner in a multiprotein network occupying the *Foxp3* promoter ([@bib34]).

In this study, we used an unbiased approach ([@bib26]) to determine binding partners to specific regions of the *Foxp3* gene promoter. As a source of protein, we used an EL4 T cell line. This cell line was shown to express *Foxp3* mRNA only upon TCR triggering with CD3-CD28 stimulation and TGF-β supplementation to the medium ([@bib41]). Because we neither stimulated the TCR nor added TGF-β during expansion of EL4 cells, we probably identified a multiprotein complex protecting this T cell line from the "side effects" of *Foxp3* gene activity. Indeed, many of the candidate proteins were repressive factors actively down-regulating basic *Foxp3* promoter activity *in vitro*. This is in line with three other recent reports identifying cyclin-dependent kinases 8 and 19, the protein Yin-Yang 1, or the long noncoding RNA Flicr as repressors of Foxp3 protein expression ([@bib1], [@bib18], [@bib56]).

Having established that our identified binding partners were *Foxp3* promoter suppressive in nature, we used a funnel approach to identify targets for further evaluation: we compared lists of factors that are down-regulated in Foxp3-expressing murine and human T~reg~ cells with our *Foxp3*-promoter-binding TFs. One interesting protein identified in the cross-comparison with both human and murine datasets was TCF1, a factor well known for its importance during thymic T cell development ([@bib3], [@bib4], [@bib44], [@bib48]). It has also been described that TCF1 protein associates with Foxp3 and, via the Wnt signaling pathway, impairs suppressive function of T~reg~ cells ([@bib43]). Testing TCF1 in a Luciferase screen, our data showed that TCF1 has *Foxp3*-promoter-suppressive capacity, and viral overexpression of TCF1 led to decreased Foxp3 expression *in vitro*. In a TCF1-deficient mouse strain, we detected an increase in a Foxp3-intermediate, but CD25-negative T cell population (CD25^-^Foxp3^int^). It is possible that, by deleting TCF1, we lowered the threshold for Foxp3 induction and thereby generated a population of CD25^-^Foxp3^int^ T cells, otherwise almost absent in lymphoid tissues. As TCF1 has a strong influence on thymic differentiation of both T cells and T~reg~ cells ([@bib3], [@bib4], [@bib44], [@bib48]), we wanted a more formal proof that TCF1 is involved in inhibiting FOXP3 expression in T~conv~ cells. Therefore, we deleted TCF1 using CRISPR-Cas9 knockout technology in primary mouse T~conv~ cells, which resulted in more Foxp3-expressing cells in the TCF1-deleted CD4^+^ T cell fraction.

Unlike in mice, in the human system, a certain percentage of T cells express FOXP3 upon activation *in vitro* ([@bib16], [@bib45], [@bib46]). To study whether activation-induced FOXP3 expression is TCF1 dependent, we used CRISPR-Cas9 technology to knockout TCF1 in human CD4 T~conv~ cells. We saw that spontaneous FOXP3 induction in activated human CD4^+^ T cells was significantly higher in TCF1-deficient T cells. This finding indicates an important function of TCF1 to suppress FOXP3 in activated non-T~reg~ CD4^+^ T cells. TCF1 expression also favors memory formation in T cells ([@bib28], [@bib42], [@bib58]). Whether TCF1 expression protects memory T cells from unintentional expression of FOXP3 has to be further evaluated.

A recent study looked at the effects of TCF1 deletion on Foxp3 expression during thymic development. The authors could show that TCF1-deficient mice harbor an increased number of Foxp3-expressing double-negative cells in the thymus ([@bib4]). In line with our data, this publication reports that TCF1 is required to prevent premature expression of Foxp3 in the thymus. Another set of publications investigated the effect of a T~reg~-specific knockout of TCF1 and Lef1 ([@bib52], [@bib54]). Both studies showed that, whereas single-gene knockouts of Lef1 or TCF1 in T~reg~ cells had no catastrophic systemic effect, deleting both genes led to autoimmune disease by impairing the immunosuppressive function of T~reg~ cells. One of these studies closely examined the effect of a T~reg~ cell-specific TCF1 deletion on T~reg~ cell homeostasis and reported no perturbation ([@bib52]). In contrast to this, we saw changes in the CD4 T cell compartment with TCF1 global knockout animals. Our animals, which also lack TCF1 in T~conv~ cells, showed the appearance of a Foxp3-intermediate, but CD25-negative T cell population (CD25^-^Foxp3^int^).

Whether our observation that TCF1 inhibits activation-induced FOXP3 expression in human and mouse conventional CD4^+^ T cells is also transferable to other T cell subsets, specifically CD8^+^ T cells, has to be further evaluated. Our mouse data showed an increased fraction of CD8^+^ T cells expressing Foxp3 in TCF1-deficient versus TCF1-sufficient animals, although the overall magnitude was lower compared with the CD4^+^ T cell compartment. Indeed, another study investigating TCF1^−/−^Lef1^−/−^ double knockout animals also reported an increased frequency of CD8^+^Foxp3^+^ T cells in the thymus ([@bib53]). The authors reported intrinsic histone deacetylase activity of the TCF1 protein. Therefore, TCF1 could change the epigenetic accessibility of the *Foxp3* gene locus to prevent unwanted Foxp3 expression.

In summary, our study shows that TCF1 might be a key factor to protect T~conv~ cells from inadvertent Foxp3 expression. This allows unperturbed effector function of T cells while preventing the regulatory phenotype associated with Foxp3 expression.

Limitations of the Study {#sec3.1}
------------------------

In this study, we present data about potential binding partners to the *Foxp3* promoter region, identified by mass spectrometry. Data were generated with a cell line (EL4), whereas follow-up experiments were conducted with primary human or murine T cells. In this article, we investigated TCF1 and the effects of overexpression or deletion on T cell biology, which could be extended by the analysis of other proteins identified with our screen.
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